The short answer
LKKTETQ (leucine, lysine, lysine, threonine, glutamate, threonine, glutamine) occupies residues 17 to 23 of thymosin beta-4 and is the motif most directly associated with its actin-binding activity. TB-500 is that motif synthesised alone with an acetylated N-terminus.
Key facts
- Sequence
- Leu-Lys-Lys-Thr-Glu-Thr-Gln
- Position in Tβ4
- Residues 17-23
- Function
- Actin binding
- Charge
- Two lysines, one glutamate
- Cysteine / methionine
- Neither present
- Free peptide MW
- 847.0 Da (CID 10169788)
Why this particular stretch
Deletion and substitution work on thymosin beta-4 localised its actin-binding activity to this internal region. That is how functional motifs are normally identified: by removing parts of a protein and observing which removal abolishes the activity. LKKTETQ emerged as the segment that could not be lost without losing actin binding.
What the residues contribute
Two lysines give the motif a strong positive charge, and actin's surface carries substantial negative charge, so electrostatic complementarity is a plausible part of the interaction. The threonines offer hydroxyls capable of hydrogen bonding, and glutamate provides a counterbalancing negative charge. It is a small, highly polar sequence with no hydrophobic core, which is consistent with a surface-binding rather than a burial interaction.
Research material referenced
TB-500 5mg, third-party HPLC tested
A motif is not a domain
The article title uses domain because that is how the material is commonly described, but a seven-residue stretch is properly a motif rather than a domain. A domain folds independently; a motif is a short functional sequence that generally does not. The distinction matters because it predicts that LKKTETQ alone will be flexible and unstructured rather than adopting a defined shape.
Why that flexibility complicates things
Within the protein, this sequence sits in a defined structural context. Isolated, it samples many conformations, only some of which resemble the bound state. That generally costs affinity (the peptide pays an entropic penalty on binding that the structured protein does not), which is one reason a motif's isolated behaviour cannot be assumed to match its behaviour in situ.
The acetylation
TB-500 carries an acetyl group on its N-terminal amine, adding 42.0 Da over the free peptide. N-terminal acetylation is a standard modification in peptide synthesis: it removes a positive charge that would not be present mid-protein, better approximating how the motif sits within the parent sequence, and it slows degradation by aminopeptidases.
Frequently asked questions
What does LKKTETQ stand for?
It is the single-letter sequence: leucine, lysine, lysine, threonine, glutamate, threonine, glutamine.
Where is it in thymosin beta-4?
Residues 17 to 23, an internal stretch of the 43-residue protein.
Why is TB-500 acetylated?
N-terminal acetylation removes a charge not present mid-protein, better approximating the motif's context, and slows aminopeptidase degradation.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedHannappel E, beta-Thymosins: Ann N Y Acad Sci 2007 (PMID 17468232)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · LKKTETQ (CID 10169788)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · TB-500 (CID 62707662)pubchem.ncbi.nlm.nih.gov
- PubMedGoldstein AL et al., Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012 (PMID 22074294)pubmed.ncbi.nlm.nih.gov
- PubMedShrivastava S et al., Thymosin beta4 and cardiac repair. Ann N Y Acad Sci 2010 (PMID 20536454)pubmed.ncbi.nlm.nih.gov
- PubMedSosne G et al., Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002 (PMID 11950239)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Thymosin β4 (RGN-259) dry eye Phase 3 (NCT03925727)clinicaltrials.gov
- PubChemPubChem · Thymosin β4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More TB-500 (Thymosin β4 fragment) articles
- How Actin Sequestration WorksThymosin beta-4 binds monomeric G-actin and holds it out of filaments. Why maintaining a monomer pool matters for how quickly a cell can rebuild its skeleton.
- How Thymosin Beta-4 Was DiscoveredLow and colleagues published the complete sequence of bovine thymosin beta-4 in PNAS in February 1981, describing it as a thymic hormone. That framing changed.
- TB-500: Structure and Where It Comes FromSeven residues taken from the middle of a 43-residue protein, with an acetylated N-terminus. What that construction implies about its properties.
- TB-500 Molecular Structure and Physical Properties889.0 Da, C38H68N10O14, no cysteine or methionine, no aromatic residue. The physical consequences of a short, highly charged, flexible peptide.
- TB-500 Storage, Stability and ReconstitutionNo cysteine, methionine or asparagine, so the usual degradation routes do not apply. Adsorption to surfaces is the loss mechanism that actually matters.